Compositions for inhibiting platelet aggregation
AssigneeMerck & Co., Inc.
InventorKarl M. Gelotte
Life of this patent
Estimating the term…
Abstract
A composition is disclosed comprising about 0.25 mg/ml 2-S-(n-Butylsulfonylamino)-3 -[4-(4-(piperdin-4-yl)butyloxylphenyl]propionic acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein the composition osmolality concentration is between about 250-310 mOsmol/kg and the pH is in the range of between 5.5-6.5.
Claims8
A composition comprising about 0.25 mg/ml 2-S-(n-Butylsulonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propioni c acid, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg and pH is in the range of between 5.5-6.5.
A composition comprising about 0.05 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic acid, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg and pH is in the range of between 5.5-6.5.
A composition formed by combining together about 0.28 mg/ml 2-S -(n-Butylsufonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propionic hydrochloride monohydrate, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihydrate, and about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg and pH is in the range of between 5.5-6.5.
A composition formed by combining together about 0.056 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl)butyloxy)phenyl]propion ic hydrochloride monohydrate, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, and about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg and pH is in the range of between 5.5-6.5.
A composition formed by combining together about 0.28 mg/ml 2-S-(n-Butylsulfonylamino)-3-[4-(4-(piperidin-4-yl) butyloxy)phenyl]propionic acid hydrochloride monohydrate, about 8 mg/ml sodium chloride, about 2.7 mg/ml sodium citrate dihdrate, and about 0.16 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 250-310 mOsmol/kg, and composition pH, adjusted if necessary with one or more pH adjusting agents, is in the range of between 5.5-6.5.
A composition formed by combining together about 0.056 mg/ml 2-S-(n-Butysulfonylamino)-3[4-(4-(piperidin-4-yl)butyloxy)phenyl]propronic acid hydrochloride monohydrate, about 9 mg/ml sodium chloride, about 0.54 mg/ml sodium citrate dihydrate, and about 0.032 mg/ml citric acid anhydrous, wherein composition osmolality concentration is between about 255-345 mOsmol/kg, and composition pH, adjusted if necessary with one or more pH adjusting agents, is in the range of between 5.5-6.5.
Dependencies are inferred from the claim text.